Quote | MoonLake Immunotherapeutics (NASDAQ:MLTX)
Last: | $44.70 |
---|---|
Change Percent: | -0.47% |
Open: | $44.95 |
Close: | $44.70 |
High: | $45.3 |
Low: | $44.09 |
Volume: | 280,811 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | MoonLake Immunotherapeutics (NASDAQ:MLTX)
2024-07-18 14:19:35 ET Summary MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is ...
2024-07-10 12:46:58 ET More on S&P Indices S & P Mid-Cap 400 Index, S&P Small Cap 600 Index, etc. Oppenheimer’s best ‘SMID-cap’ ideas for 2024 S&P 400 rejig: HTZ, PENN to exit index; Illumina moves down from S&P 500 Read the...
Message Board Posts | MoonLake Immunotherapeutics (NASDAQ:MLTX)
Subject | By | Source | When |
---|---|---|---|
MoonLake Immunotherapeutics (NASDAQ: MLTX) 10% owner Bihua Chen | crudeoil24 | investorshub | 04/20/2022 4:59:07 PM |
News, Short Squeeze, Breakout and More Instantly...
MoonLake Immunotherapeutics Company Name:
MLTX Stock Symbol:
NASDAQ Market:
MoonLake Immunotherapeutics Website:
2024-06-23 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a collaboration agreement with SHL Medical,...
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New...